Nurtec ODT (Rimegepant Sulfate) Patent Expiration, LOE Window & CMS Spending

Nurtec ODT (Rimegepant Sulfate) by Pfizer: FDA Orange Book core substance LOE 2034-02-27 (last listed 2039-03-25), 0 AB generics, $1.14B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN212728 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-02-27
Last Listed Patent or Exclusivity Date2039-03-25
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.14B
2024 Medicare Part D Spend$625.2M
2024 Medicaid Spend$513.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.